Lubiprostone

Indications

Lubiprostone is used for: Irritable Bowel Syndrome with Constipation (IBS-C), Chronic idiopathic constipation

Adult Dose

Oral Chronic idiopathic constipation Adult: 24 mcg bid daily. Irritable Bowel Syndrome With Constipation 8 mcg twice daily. Opioid-Induced Constipation Treatment in patients with chronic noncancer pain 24 mcg bid daily. Hepatic impairment Mild: Dose adjustment not necessary Moderate (Child-Pugh B): Chronic idiopathic or opioid-induced constipation, 16 mcg PO q12hr; irritable bowel syndrome with constipation (IBS-C), no dosage adjustment required Severe (Child-Pugh C): Chronic idiopathic or opioid-induced constipation, 8 mcg PO q12hr; IBS-C, 8 mcg PO q24hr

Child Dose

Safety and efficacy not established

Renal Dose

Administration

Should be taken with food.

Contra Indications

History of mechanical GI obstruction.

Precautions

Safety has not been established in pregnant women. Not to be used in patients with severe diarrhoea. Lactation: Unknown whether drug is excreted in breast milk; because lubiprostone increases fluid secretion in the intestine and intestinal motility, monitor breastfeeding infants for diarrhea

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Lubiprostone : >10% Nausea (29%),Headache (12%),Diarrhea (11%) 1-10% Edema (3%),Chest discomfort (2%),Peripheral edema (1-3%),Fatigue (2%),Dizziness (3%),Flatulence (4-6%),Abdominal distress (3%),Dyspepsia (2%),Xerostomia (1%),Abdominal pain (4-8%),Loose stools (3%)

Mechanism of Action

Lupristone is a locally-acting chloride-channel activator that increases intestinal secretion. In doing so, it increases intestinal motility, thus aiding the passage of stool and relieve the symptoms associated with chronic idiopathic constipation.